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Abstract 
Sphingolipid biosynthesis begins with the condensation of l-serine and palmitoyl-CoA catalyzed by 
the PLP-dependent enzyme serine palmitoyltransferase (SPT). Mutations in human SPT cause 
hereditary sensory autonomic neuropathy type 1, a disease characterized by loss of feeling in 
extremities and severe pain. The human enzyme is a membrane-bound hetereodimer, and the most 
common mutations are located in the enzymatically incompetent monomer, suggesting a “dominant” 
or regulatory effect. The molecular basis of how these mutations perturb SPT activity is subtle and is 
not simply loss of activity. To further explore the structure and mechanism of SPT, we have studied 
the homodimeric bacterial enzyme from Sphingomonas paucimobilis. We have analyzed two mutants 
(N100Y and N100W) engineered to mimic the mutations seen in hereditary sensory autonomic 
neuropathy type 1 as well as a third mutant N100C designed to mimic the wild-type human SPT. The 
N100C mutant appears fully active, whereas both N100Y and N100W are significantly compromised. 
The structures of the holoenzymes reveal differences around the active site and in neighboring 
secondary structure that transmit across the dimeric interface in both N100Y and N100W. 
Comparison of the l-Ser external aldimine structures of both native and N100Y reveals significant 
differences that hinder the movement of a catalytically important Arg
378
 residue into the active site. 
Spectroscopic analysis confirms that both N100Y and N100W mutants subtly affect the chemistry of 
the PLP. Furthermore, the N100Y and R378A mutants appear less able to stabilize a quinonoid 
intermediate. These data provide the first experimental insight into how the most common disease-
associated mutations of human SPT may lead to perturbation of enzyme activity. 
 
Introduction 
Sphingolipids are ubiquitous constituents of eukaryotic cells, where they play important roles in 
signaling, differentiation, and apoptosis 
[1–4]
. Defects in sphingolipid catabolism have been linked to 
several human diseases, such as hypertension, cancer, and disorders of the peripheral nervous system. 
The most common inherited peripheral neuropathy is hereditary sensory autonomic neuropathy type 1 
(HSAN1).
[6]
 The disease leads to progressive loss of sensation in extremities and is often associated 
with searing pain 
[5–8]
. Genetic studies by two independent groups mapped the disease-associated 
mutations to the lcb1 (long chain base 1) gene on chromosome 9q22, which encodes the SPT1 subunit 
of serine palmitoyltransferase (SPT; EC 2.3.1.50) 
[9–11]
. SPT catalyzes the first and rate-limiting step 
of the sphingolipid biosynthetic pathway in all organisms studied to date 
[12]
. The reaction is a 
pyridoxal 5′-phosphate (PLP)-dependent, decarboxylative, Claisen condensation of the amino acid l-
serine and the long chain (C16) fatty acid palmitoyl-CoA, which produces the sphingolipid precursor, 
3-ketodihydrosphingosine (KDS). 
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SPT belongs to the α-oxoamine synthase subfamily of PLP-dependent enzymes, which contains three 
other well characterized members: 8-amino-7-oxononanoate synthase (AONS) 
[13, 14]
, 5-
aminolevulinate synthase (ALAS) 
[15–17]
, and 2-amino-3-ketobutyrate-CoA ligase (KBL) 
[18]
. These 
enzymes catalyze the Claisen-like condensation between an amino acid and an acyl-coenzyme A 
thioester 
[19]
. A common mechanism has been proposed 
[12, 14, 20–23]
 comprising the following steps: 
formation of an external aldimine via displacement of the lysine-PLP internal aldimine (holo-SPT) by 
the incoming amino acid substrate; formation of a quinonoid intermediate by abstraction of the α-
proton from the PLP-amino acid external aldimine; a Claisen condensation with the fatty acid-CoA 
thioester substrate, followed by displacement of the CoASH to form a β-ketoacid intermediate; 
decarboxylation of this species to form a product quinonoid; protonation of this quinonoid to form the 
product external aldimine; and finally release of the α-oxoamine product and regeneration of the 
enzyme PLP-internal aldimine (Fig. 1). Structural studies have shown AONS, ALAS, and KBL 
isoforms from various species to be homodimers 
[13, 17, 18]
. In marked contrast, eukaryotic SPTs are 
heterodimeric, membrane-bound proteins consisting of two subunits, SPT1 and SPT2 (encoded by the 
lcb1 and lcb2 gene, respectively) 
[24]
. 
 
 
Figure 1. Proposed catalytic mechanism of SPT: a, the internal aldimine (holo-SPT) is displaced by 
l-serine to form the external adlimine; b, binding of second substrate palmitoyl-CoA causes 
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conformational change to give the Dunathan intermediate; c, formation of the quinonoid by 
deprotonation of Cα hydrogen; d, thioester bond hydrolysis and release of CoASH to give β-keto acid 
intermediate; e, decarboxylation to form KDS product quinonoid; f, reprotonation to form KDS 
product external aldimine; g, KDS product release and reformation of the holo-form. The l-serine 
external aldimine has been trapped in the current study. The dotted line shows that steps e and f may 
be bypassed by an alternative mechanism that does not proceed via a product quinonoid (see ref.
[21]
). 
Analysis of a number of HSAN1 patients has revealed the four most common mutations to be 
C133W, C133Y, V144D, and G387A, with the cysteine mutations appearing to be the most prevalent 
in populations 
[10, 25]
. The impact that these mutations have on SPT activity and sphingolipid 
metabolism has been the focus of attention by a number of groups. Most surprisingly, these disease-
associated mutations occur in the SPT1 monomer, a protein that must be inactive, since it lacks the 
key lysine, histidine, and aspartate residues necessary to bind and stabilize the PLP cofactor. It is the 
SPT2 protein that contains the conserved, active site lysine residue that forms a Schiff base internal 
aldimine with the PLP. However, both subunits are essential to produce functionally active SPT 
heterodimer 
[26–29]
, indicating that the inactive subunit has a crucial role in function. Dunn and co-
workers 
[30] 
created several mutations in the yeast lcb1 and lcb2 genes, including those corresponding 
to the HSAN1 SPT1 mutations, and found that they dominantly inhibit SPT activity. A transgenic 
mouse model also revealed that the LCB1 C133W mutation led to mice with decreased tissue SPT 
activity and HSAN1 symptoms despite unaltered ceramide concentrations 
[31]
. A different study found 
that SPT activity was decreased in the tissues of HSAN1 patients, and in a Chinese hamster ovary 
model, hamster LCB1 C133Y and C133W mutations could not rescue cells lacking endogenous 
LCB1 
[32]
. These combined studies revealed that the HSAN1 mutations act directly on the SPT 
enzyme but the pathological consequence on sphingolipid metabolism is unclear. Very recently, Dunn 
and colleagues discovered a small 80-amino acid protein (TSC3p) in yeast that stimulated yeast SPT 
activity, but its role is still unclear 
[33]
. Recently, a third eukaryotic subunit (SPT3) has been 
characterized and appears to be required for optimum SPT activity, although it is expressed most 
highly in placental tissue and human trophoblasts 
[34]
. It has been suggested that these three subunits 
could form a higher order SPT complex 
[35]
. The instability and hydrophobic nature of eukaryotic 
SPTs has made their isolation and therefore biophysical characterization particularly challenging 
[24, 
36–38]
. 
We have targeted homodimeric SPT from Sphingomonas paucimobilis EY2395 to provide molecular 
insight into the enzymatic properties of SPT 
[39, 40]
. Recently, we reported the first high resolution x-
ray crystal structure of the S. paucimobilis holo-SPT 
[41] 
and showed that the active site containing the 
PLP cofactor is at the dimer interface. We used this structure to model the human enzyme and map 
the human cysteine residue (Cys
133
) of SPT1 onto Asn
100
 of the bacterial SPT 
[41]
. We found that 
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Asn
100
 is proximal to the PLP binding site and lies at the dimer interface. To explore the effects of the 
HSAN1 mutations on human SPT activity and structure, we have studied mutants of the bacterial 
enzyme. We made the N100C mutant to better mimic native human SPT and N100W and N100Y to 
mimic the most common mutations in human SPT. We have characterized the mutations using 
kinetics, spectroscopy, and structural biology, including structures of the external l-Ser aldimine. 
These data provide molecular insights into the effects of HSAN1 mutations. Also, as part of these 
studies, we identify residues that play a role in the stabilization of intermediates in the SPT reaction 
and have been able to generate new insights into the substrate specificity and mechanism of the α-
oxamine synthase family. 
 
Experimental procedures 
Chemicals 
Plasmids and Escherichia coli competent cells were purchased from Novagen, and all 
chromatography columns were from GE Healthcare. All buffers and reagents were from Sigma. 
Palmitoyl-CoA was from Fluka and Avanti Lipids, and [U-
14
C]l-serine (specific activity 1.85 
MBq/ml) was from GE Healthcare. The QuikChange site-directed mutagenesis kit was purchased 
from Stratagene. The decanoyl-CoA (10:0), lauroyl-CoA (12:0), myristoyl-CoA (14:0), stearoyl-CoA 
(18:0), and arachidoyl-CoA (20:0) were from Sigma. Oligonucleotide primers were sourced from 
SigmaGenosys. PEG 3350 was from Fluka. S-(2-oxoheptadecyl)-CoA was a kind gift from Dr. 
Hiroko Ikushiro (Department of Biochemistry, Osaka Medical College, Japan). 
 
Cloning and Expression of S. paucimobilis SPT N100W, N100Y, N100C, R378A, and R378N 
Mutants in E. coli 
Plasmid pET-28a/SPT WT was used as the template for mutations (N100W, N100Y, N100C, R378A, 
and R378N) that were introduced into the SPT gene by site-directed mutagenesis using the following 
mutagenic primers (the mutagenic bases are shown in boldface type) and confirmed by big Dye 
sequencing: 5′-GGGTCGGGCACCTGGGGCAGCCGGATG-3′ (SPT N100W forward), 5′-
CATCCGGCTGCCCCAGGTGCCCGACCC-3′ (SPT N100W reverse), 5′-
GGGTCGGGCACCTATGGCAGCCGGATG-3′ (SPT N100Y forward), 5′-
CATCCGGCTGCCATAGGTGCCCGACCC-3′ (SPT N100Y reverse), 5′-
GGGTCGGGCACCTGTGGCAGCCGGATG-3′ (SPT N100C forward), 5′-
CATCCGGCTGCCACAGGTGCCCGACCC-3′ (SPT N100C reverse), 5′-
CTCTACGTCAACATGGCGGCCCCGCCC-3′ (SPT R378A forward), 5′-
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GGGCGGGGCCGCCATGTTGACGTAGAG-3′ (SPT R378A reverse), 5′-
CTCTACGTCAACATGGCGAACCCGCCC-3′ (SPT R378N forward), and 5′-
GGGCGGGTTCGCCATGTTGACGTAGAG-3′ (SPT R378N reverse). 
The recombinant plasmids were used to transform E. coli BL21 (DE3) competent cells, and selection 
was carried out on LB agar containing 30 μg/ml kanamycin. For each mutant (and native), a single 
colony was used to inoculate 500 ml of 2YT broth (16 g/liter Bacto-tryptone, 10 g/liter Bacto-yeast 
extract, 5 g/liter sodium chloride (pH 7.5)), which was shaken at 250 rpm overnight at 37 °C. The 
overnight culture was added to 4 liters of 2YT broth supplemented with kanamycin and grown at 37 
°C to an A600 of 0.6. Protein expression was induced by the addition of isopropyl 1-thio-β-d-
galactopyranoside to give a final concentration of 0.1 mm, and growth was continued for 5 h at 30 °C. 
Cells were harvested (Sorvall RC5B centrifuge) by centrifugation at 3500 rpm for 20 min at 4 °C. 
 
Purification of SPT WT, N100W, N100Y, N100C, R378A, and R378N 
The proteins were purified essentially according to the previously described method, which is based 
polyhistidine-tagged protein binding to Ni
2+
-nitrilotriacetic acid-agarose (Qiagen) 
[41]
. After elution, 
fractions were pooled and desalted by dialysis against 20 mM potassium phosphate (pH 7.5), 150 mM 
NaCl, and 25 μM PLP. A gel filtration step (Sephacryl S200 26/60 HR; GE Healthcare) was carried 
out in the same buffer. For enzymatic assays and UV-visible spectroscopy, this buffer is also used. 
For x-ray crystal trials, the protein was exchanged into 10 mM Tris (pH 7.5), 150 mM NaCl, and 25 
μM or 250 μM PLP. For storage, the enzymes were transferred to the same buffer containing 20% 
glycerol (v/v) and stored at −80 °C until use. Protein identity and integrity were confirmed by high 
pressure liquid chromatography electrospray mass spectrometry on a MicroMass Platform II 
quadrupole mass spectrometer equipped with an electrospray ion source. The experimentally 
determined masses of recombinant S. paucimobilis SPT WT and each of the mutants were within 
0.1% of the theoretical mass, which includes the C-terminal LEHHHHHH fusion affinity tag with the 
enzyme lacking the N-terminal methionine 
[41]
. 
 
Spectroscopic Measurements 
All UV-visible spectra were recorded on a Cary 50 UV-visible spectrophotometer (Varian) and 
analyzed using Cary WinUV software (Varian). Prior to enzymatic assays, SPT was converted to the 
holo-form by dialysis against freshly prepared 20 mM potassium phosphate (pH 7.5) containing 150 
mM NaCl and 25 μM PLP for 1 h at 4 °C. Excess PLP was removed by passing the protein through a 
PD-10 (Sephadex G-25M) desalting column (GE Healthcare) before concentration to 10–20 mg/ml 
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using a VivaSpin 30 kDa cut-off concentration filter. For UV-visible assays, the concentration of 
recombinant SPT was 10 μM, and the spectrophotometer was blanked with 20 mM potassium 
phosphate (pH 7.5) containing 150 mM NaCl. 
 
Determination of Dissociation Constants 
Assays were carried out in 0.5-ml quartz cuvettes (1-cm path length) and typically contained 10 μM 
SPT in 20 mM potassium phosphate (pH 7.5). Varying amounts of L-serine (0–80 mM) were used in 
each assay. After the addition of substrate, the reactants were mixed and allowed to equilibrate for 15 
min at 25 °C. Small base-line changes were corrected using Sigma Plot software. Changes in 
absorbance at 425 nm (SPT WT, N100C, R378A, and R378N) and 420 nm (SPT N100W and N100Y) 
were plotted against L-serine concentrations, and data points were fitted to a hyperbolic saturation 
curve (Equation 1) using Sigma Plot software, 
 
 
 
where ΔAobs represents the observed change in absorbance at 422 nm, and ΔAmax is the maximal 
absorbance change, [serine] is the L-serine concentration, and Kd is the dissociation constant (Table 
1). The errors are asymptotic S.E. values of each parameter derived from the curve fitting procedure 
within Sigma Plot, and values were reproducible across a number of enzyme preparations. 
 
SPT WT, N100Y, and R378A Quinonoid Formation 
Assays were carried out in 0.5-ml quartz cuvettes and typically contained 5 μMSPT in 20 mM 
potassium phosphate (pH 7.5). To this 45 mM L-serine and 1.45 mMS-(2-oxoheptadecyl)-CoA were 
added in the assay. After the addition of the substrate, the reactants were mixed and allowed to 
equilibrate for 20 min at 25 °C. The spectroscopic data were recorded between 200 and 800 nm. Small 
base-line changes were corrected using Sigma Plot software. 
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Assay of Recombinant SPT Activity 
The activity of SPT was measured by monitoring the formation of [
14
C]KDS. A final enzyme 
concentration of 10 μM SPT in 20 mM potassium phosphate buffer, pH 7.5, 150 mM NaCl) was 
incubated with 20 mM [U-
14
C]L-serine (9250 Bq, 0.250 μCi; GE Healthcare) and 1.6 mM palmitoyl-
CoA in a final volume of 125 μl. The reaction was incubated at 37 °C for 20 min, and then the 
reaction was quenched by the addition of 30 μl of 2.0 M NH4OH (final concentration 0.4 M). This 
was then extracted with an equal volume of CHCl3/CH3OH (2:1, v/v). The sample was centrifuged at 
13,000 rpm for 5 min, and the aqueous phase was discarded before the organic phase was allowed to 
evaporate overnight. The resulting lipid residue was resuspended in 15 μl of CHCl3/CH3OH (2:1, v/v) 
and spotted onto a silica gel 60 TLC plate. Separation was carried out with a mobile phase of 
CHCl3/CH3OH/NH4OH (40:10:1, v/v/v), using a KDS reference standard (Matreya). The TLC was 
developed with a Storage PhosphorImager (GE Healthcare) for 4 days at room temperature, and the 
phosphor screen was visualized using ImageJ software. 
SPT activity was also measured using a continuous spectrophotometric assay by monitoring the 
release of CoASH from acyl-CoA substrates and reaction with 5,5′-dithiobis-2-nitrobenzoic acid 
(DTNB) 
[42]
. Assays were carried out in 0.5-ml cuvettes in a Varian Cary-50 UV-visible 
spectrophotometer. The enzyme was incubated with L-serine in a buffered solution containing DTNB, 
and the assay was started by the addition of the second substrate, palmitoyl-CoA. The CoASH thiol 
product was monitored by observation of the TNB
−
 anion at 412 nm ϵmax = 14,150 M
−1
 cm
−1
 
[43]
. Initial 
rates were measured at increasing concentrations ofL-serine (0.12–50 mM) while maintaining 
palmitoyl-CoA in excess. A typical experiment to determine the Km value for L-serine contained 0.16 
μM SPT, 0.1–50 mM L-serine, 250 μM palmitoyl-CoA, and 0.2 mM DTNB in 50 mM potassium 
phosphate buffer, pH 7.5. Kinetic constants (kcat and Km values; Table 1) were calculated from 
Michaelis-Menten plots using Sigma Plot. Kinetic constant values were calculated in a similar way for 
CoA substrates (decanoyl, lauroyl, myristoyl, palmitoyl, stearoyl, and arachidoyl) but by maintaining 
L-serine (100 mM) in excess (Table 2). As a check, the kcat/Km parameters for CoA substrates were 
also determined by the method of complete condensation when [CoA] was ≪Km. In this case, kcat/Km 
is calculated at a single substrate concentration as an observed rate constant (kobs) by monitoring 
disappearance of the substrate. The data were fitted to the equation, A = Alim × (1 − exp(−kobs × t)), 
where A is the absorbance at 412 nm, Alim is the limiting absorbance value when the substrate has 
completely disappeared, kobs is the observed rate constant, and t is the time in seconds. The errors are 
asymptotic S.E. values of each parameter derived from the curve fitting procedure within Sigma Plot. 
The values obtained were reproducible over a number of enzyme preparations, and the errors can be 
used as a gauge of the fitted curve's accuracy and were generally less than 5% of the value of the 
parameter. 
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Structural Biology 
The three mutant proteins were screened for suitable crystallization conditions at the Scottish 
Structural Proteomics Facility. The proteins were dialyzed in the presence of excess PLP to ensure 
complete reloading prior to crystallization. Conditions used to obtain crystals of the wild-type/PLP 
protein 
[41]
 were used as a starting point to formulate stochastic optimization screens using software 
developed in house. The screens were built on a Hamilton Microstar liquid-handling robot controlled 
by Rhombix system software (Thermo). Crystallization trials were set up in hanging drop plates 
(EasyXtal DG-CrystalSupport; Qiagen) using 2–3 μl of the protein solution and 1 μl of well solution 
in the hanging drop. 
Crystals of the mutant SPTs were obtained in the form of yellow plates corresponding to the high 
resolution form of the holo wild-type SPT. The SPT N100W mutant was crystallized at 20 mg/ml in 
10 mM Tris (pH 7.5), 150 mMNaCl, 25 μM PLP using a well solution of 0.1 M MgCl2, 22% (w/v) 
PEG 3350, and 0.10 M Hepes (pH 6.5). The N100Y mutant was crystallized at 20 mg/ml in 10 
mMTris (pH 7.5), 150 mM NaCl, 250 μM PLP, using a well solution of 0.15 M MgCl2, 22% (w/v) 
PEG 3350, and 0.10 M Hepes (pH 6.5). Finally, the N100C mutant was crystallized at 20 mg/ml in 10 
mM Tris (pH 7.5), 150 mM NaCl, 250 μM PLP, using a well solution of 0.1 M MgCl2, 27% (w/v) 
PEG 3350, and 0.10 M Hepes (pH 6.5). 
The solutions used for equilibrating harvested crystals varied slightly according to the crystallization 
conditions and consisted of 22–29% PEG 3350 (w/v), 0.1 MHEPES (pH 6.5), 0.08–0.12 M MgCl2. 
All crystals used for data collection were soaked for a few minutes in the respective equilibrating 
solution plus 1–2 mMPLP. Additionally, the external aldimine form of the SPT wild-type was 
produced by soaking the crystal in the equilibrating solution plus 5 mM L-serine for 10 min, and that 
of the N100Y mutant was produced by soaking the crystal in the equilibrating solution plus 50 mM L-
serine for 15 min at room temperature. The crystals were mounted in a cryo-loop (Molecular 
Dimensions) and cryo-protected in solutions varying slightly for each crystal and containing the 
equilibrating solutions plus 15–20% PEG 400 (v/v). The crystals were then frozen by plunging them 
into liquid nitrogen and carried in a dry cryogenic Dewar to the European Synchrotron Radiation 
Facility (Grenoble, France) for data collection. The data sets were collected at 100 K to varying 
resolutions using three different beam lines (supplemental Table 1). The data for the wild-type serine 
external aldimine were processed with Mosflm and scaled with Scala from the CCP4 suite of 
programs 
[44]
. The data for the N100C, N100Y, N100W, and N100Y serine external aldimine 
structures were processed using XDS and scaled using XSCALE (available on the World Wide Web) 
[45]
. 
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Analysis of the density revealed that the PLP was covalently bound to Lys
265
 in every mutant, 
confirming that we had obtained the holo-form of the proteins. All mutant models were refined using 
Refmac5 
[46]
 and manually adjusted, including the addition of water molecules with WinCoot 
[47]
. Data 
and structures have been deposited in the Protein Data Bank. Density was clearly visible to the 
N100W mutation, but we could not satisfactorily locate the tryptophan side chain; there is disordered 
electron density, which indicates multiple conformations. 
 
Results 
Spectroscopic Properties of SPT N100 Mutants 
The three mutants were obtained in milligram quantities as the internal aldmine, holo-form, 
confirming their capacity to bind the PLP cofactor (Fig. 2). The SPT N100C mutant has absorbance 
maxima at 335 and 425 nm, akin to the wild-type SPT values of 340 and 425 nm (Fig. 2, A and B). In 
both native and N100C, the enolimine peak at 335 nm is dominant, indicating that the PLP cofactor is 
in a very similar chemical environment in both proteins. In contrast, the UV-visible spectra of the SPT 
N100W and N100Y mutants have maximum absorbance values at 340 and 415 nm (Fig. 2, C and D). 
We noted that the ketoenamine peak (415 nm) had not only blue-shifted; it had also become the 
dominant form in the spectrum in these enzymes. These differences suggest a common perturbation in 
the PLP binding site of the mutants compared with the wild type (Fig. 2, C and D,solid lines). The 
ability of the mutants to form the external aldimine form by binding L-serine was measured by the 
addition of increasing concentrations of the amino acid (ranging between 0 and 100 mM). This 
addition resulted in an increase of the absorbance at 425 nm for the wild-type and the N100C enzyme. 
Titration of L-serine into the SPT N100W and N100Y mutants led to a small shift of a few nm to a 
longer wavelength. Although all mutants form the external aldimine, the N100W and N100Y mutants 
have clear differences (Fig. 2, A–D). By measuring the change in absorbance at ketoenamine-specific 
wavelengths that are specific to the external aldimine, the apparent serine dissociation constants 
(Kd
Ser
) have been determined for the wild type SPT and each of the mutants (Table 1). The wild-type 
SPT Kd
Ser
 is 1.1 mM, in good agreement with the Kd
app
 found by Ikushiro et al. 
[40]
 (1.4 mM). A 
similar Kd
Ser
 was obtained for the N100C mutant (2.7 mM; ∼2.5-fold higher). Higher KdSer values 
were obtained for two SPT mutants: N100W, 16.2 mM, a ∼15-fold increase, and N100Y, 7.5 mM, a 
∼7-fold increase, compared with the wild-type SPT. 
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Figure 2. UV-visible analysis of SPT wild-type and mutants: Absorbance spectra of S. 
paucimobilis SPT wild-type (A) and mutants N100C (B), N100W (C), and N100Y (D). In spectrum A 
the enolimine (335 nm) and ketoenamine (420 nm) forms of the external aldimine are drawn. Thesolid 
line in each spectrum is the holo-form of the enzyme (10 μM SPT, 20 mM potassium phosphate 
buffer (pH 7.5), 150 mM NaCl, 25 °C). Increasing concentrations of L-serine were added (0, 0.1, 0.5, 
1, 2, 5, 10, 20, and 40 mM; dotted and dashed lines), and the spectrum was recorded after 15 min. For 
the SPT N100C, N100W, and N100Y spectra the final concentrations of L-serine were 0, 0.1, 0.5, 1, 
2, 5, 10, 20, 40, 60, and 80 mM. AU, absorbance units. 
 
Enzyme kcat × 10
3
 Km
Ser
 Km
PCoA
 kcat/Km
Ser
 Kd
Ser
 
 
s
−1
 mM μM M−1 s−1 mM 
SPT WT 1150.0 ± 30.0 1.4 ± 0.1 35.4 ± 2.0 821.4 1.1 ± 0.1 
SPT N100C 250.0 ± 4.0 7.0 ± 0.4 60.0 ± 9.8 35.7 2.7 ± 0.2 
SPT N100W 9.0 ± 0.4 1.6 ± 0.4 19.3 ± 2.2 5.6 16.2 ± 3.1 
SPT N100Y 5.0 ± 0.1 2.5 ± 0.4 31.4 ± 3.3 2.0 7.5 ± 0.5 
SPT R378A 78.3 ± 3.2 3.8 ± 1.0 39.2 ± 3.1 20.5 1.1 ± 0.1 
SPT R378N 33.0 ± 1.0 2.4 ± 0.2 31.0 ± 6.0 13.8 3.1 ± 0.2 
 
Table 1. Kinetic parameters for the purified SPT wild-type and mutant enzymes. 
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KDS Formation by SPT WT and Mutants 
The ability of each enzyme to convert [
14
C]L-serine and palmitoyl-CoA to the product [
14
C]KDS was 
examined (Fig. 3A), using the method previously described 
[48]
. The N100C mutant showed an activity 
similar to the wild-type SPT; however, both the N100W and N100Y mutants showed a large decrease 
in activity (∼84%) compared with the wild-type enzyme (with saturating substrate concentrations) [41]. 
The R378N and R378A produced 50 and 40% KDS, respectively, in comparison with the wild-type 
enzyme (Fig. 3B). 
 
 
Figure 3. Assay of SPT activity: A and B, TLC of radiolabeled products obtained by SPT-catalyzed 
conversion of L-serine and palmitoyl-CoA to [
14
C]KDS. Recombinant holo-SPT was incubated with 
U-
14
C-labeledL-serine and palmitoyl-CoA for 20 min at 37 °C. The assay was stopped by the addition 
of NH4OH and extracted with an equal volume of chloroform/methanol (2:1, v/v). Organic phases 
were removed, dried, separated by TLC, and analyzed by a PhosphorImager. The arrowmarks the 
position of the standard KDS. A, products observed after reaction of the SPT N100C (lane 1), SPT 
N100W (lane 2), SPT N100Y (lane 3), and SPT WT (lane 4). B, products observed after reaction of 
the SPT WT (lane 1), SPT R378A (lane 2), and SPT R378N (lane 3). C, kinetic analysis of wild-type 
SPT using a spectrophotometric assay. i, initial rates of CoASH release measured 
spectrophotometrically at 412 nm and at several final concentrations of L-serine: 6.25 mM (a), 1.56 
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mM(b), 0.78 mM (c), 0.39 mM (d), and 0.12 mM (e). Each assay contained 0.16 μM enzyme, 250 μM 
palmitoyl-CoA, and 0.2 mM DTNB. ii, the initial rates were converted to kcat
app
 values and plotted 
against L-serine concentration to determine the Km and kcat parameters. iii, complete condensation of 5 
μM palmitoyl-CoA by 0.57 μM wild-type SPT in the presence of 100 mM L-serine. kcat/Km for 
palmitoyl-CoA was calculated by dividing kobs by the enzyme concentration. 
 
Kinetic Analyses of Wild-type, HSAN1 Mimics, and Arg
378
 Mutants 
The raw data for wild-type SPT are shown in Fig. 3C. The SPT WT bound L-serine and palmitoyl-
CoA with Km values of 1.4 mM and 35.4 μM, respectively (Table 1). The enzyme turned over with a 
kcat of 1.150 s
−1
 and an efficiency (kcat/Km) of 821.4 M
−1
 s
−1
 for L-serine. We observed kcat/Km values of 
35.7, 5.6, and 2.0 M
−1
s
−1
 for the mutant SPTs N100C, N100W, and N100Y, respectively. The lower 
values observed for the HSAN1 mimics N100W and N100Y (147- and 410-fold respectively) confirm 
that the mutations have had an impact on catalysis. We attribute the lower value for the N100C 
mutant (23-fold lower) to reactivity of the Cys
100
 thiol with the DTNB reagent (data not shown), since 
this mutant showed comparable KDS formation in the radioactive assay. The coupled assay was used 
to investigate the chain length specificity of wild-type SPT with various acyl-CoA substrates. We 
found palmitoyl-CoA (C16:0) to have the fastest turnover (kcat = 1.150 s
−1
) of all of the acyl-
thioesters, with a Km of 35.4 μM (Table 2). When comparing the kcat/Km values, stearoyl-CoA (C18:0) 
was the most efficient substrate (65,547 M
−1
 s
−1
). The thioester with the longest chain, arachidoyl-
CoA (C20:0) was a good substrate, with a Km of <10 μM, but below this concentration, accurate rates 
could not be determined due to the limit of detection with the DTNB reagent. In contrast, the shortest 
substrate, decanoyl-CoA (C10:0), was the poorest substrate in terms of binding and turnover. In the 
first study of S. paucimobilis SPT carried out by Ikushiro et al. 
[39]
, they found a similar trend, with 
palmitoyl-CoA (C16) being the best substrate matching the human SPT. The recently discovered, 
unusual fused, viral SPT displayed highest activity with myristoyl-CoA (C14) 
[12, 49]
. 
 
Acyl-CoA kcat Km
CoA
 kcat/Km
CoA
 
 
s
−1
 μM M−1 s−1 
Decanoyl (10:0) 0.045 ± 0.002 2324.9 ± 175.1 19.4 
Lauroyl (12:0) 0.262 ± 0.006 822.2 ± 32.6 318.7 
Myristoyl (14:0) 0.601 ± 0.012 97.1 ± 5.1 6189.5 
Palmitoyl (16:0) 1.150 ± 0.030 35.4 ± 2.0 32,485.9 
Stearoyl (18:0) 0.898 ± 0.012 13.7 ± 0.8 65,547.4 
Arachidoyl (20:0) 0.327 ± 0.014 <10 >32,700 
 
Table 2. Chain length specificity of wild-type SPT. 
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Similar analysis was also carried out on the SPT R378A and R378N mutants. These bound PLP in a 
manner similar to wild-type with absorbance maxima at 335 and 425 nm (data not shown). The values 
obtained were similar to that of the wild-type SPT (Kd
Ser
 values of 1.1 and 3.1 mM for the R378A and 
R378N, respectively). Using the coupled spectrophotometric assay, we measured 60- and 40-fold 
decreases in kcat/Km
Ser
 for each mutant (R378A and R378N, respectively; Table 1). 
 
SPT WT, N100Y, and R378A Quinonoid Formation 
The ability of the wild-type enzyme and both the N100Y and R378A mutants to form a quinonoid 
intermediate was tested by the addition of a thioether analogue of palmitoyl-CoA reported by Ikushiro 
et al. 
[50]
. The addition of the analogue to the L-serine external aldimine form of the wild-type enzyme 
led to the appearance of a clear peak at 495 nm due to the quinonoid (increase in absorbance ∼0.06), 
in agreement with that found previously (Fig. 4A). In contrast, the SPT N100Y mutant, under the 
same conditions, produced a small, broad shoulder 490–500 nm (increase in absorbance ∼0.01 
absorbance units; Fig. 4B). We could not observe the formation of a quinonoid species at all in the 
R378A mutant (Fig. 4C). 
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Figure 4. Quinonoid formation in the wild-type SPT, N100Y, and R378A mutants: UV-visible 
spectra of the SPT wild type (A), N100Y (B), and R378A (C) external aldimine forms after titration of 
the thioether analog (S-(2-oxoheptadecyl)-CoA) of palmitoyl-CoA. Incubations were carried out with 
5 μM enzyme, 45 mM L-serine, 1.4 mM analog, 20 mMpotassium phosphate buffer (pH 7.5), 150 
mM NaCl for 15 min at 25 °C. The solid line in each spectrum represents the holo-form; the dotted 
line is the external aldimine form after the addition of L-ser; and thedashed line is after the addition of 
the analogue. An absorbance maximum at 495 nm (marked with an arrow), attributed to a quinonoid 
species (50), is clearly observed in the wild-type enzyme, but only a broad shoulder is produced in the 
N100Y mutant, and no peak is observed for the R378A mutant. AU, absorbance units. 
 
The Structure of the Wild-type SPT·L-Ser External Aldimine Complex 
The dimeric form of the L-Ser external aldimine SPT complex is shown in Fig. 5A. Of course, the 
major difference between the internal (holo-) and external aldimine forms is that in the internal 
adimine, the Schiff base is between Lys
265
 of the protein and the PLP co-factor, whereas in the L-Ser 
external aldimine, this C–N bond has broken. The PLP·L-ser external aldmine is clearly observed in 
the electron density (Fig. 5B). An overlay of the structures of the internal 
[41]
and external aldimine 
shows an r.m.s. deviation of 0.3 Å and reveals that most of the interactions between the enzyme and 
the PLP cofactor are unchanged. In both structures, the PLP hydrogen-bonds to the side chains of 
Asp
231
, His
234
, Thr
262
, and Ser
264
, the main chain of Gly
134
 and Thr
135, and π-stacks with His159. His159 
is conserved throughout all of the members of the α-oxoamine synthase family [41]. As a result of 
external aldimine formation, the PLP has shifted, essentially rotating around the phosphate, with the 
Schiff base nitrogen moving over 1.5 Å. Lys
265
 adopts a different conformation as a result of breaking 
its link to PLP and now makes a hydrogen bond with the hydroxyl of the L-ser component of the 
external aldimine (Fig. 6A). Accompanying the change in Lys
265
conformation, Tyr
73
 substantially 
alters its position. The carboxylate group of L-Ser hydrogen-bonds to the conserved His
159
 and makes 
a salt link with Arg
378, which has “swung” into the active site. In the native structure, this residue is at 
the end of a β-strand and hydrogen-bonded to the side chain of Gln357. In order to make the salt 
contact, the β-strand has been disrupted, and the Cα of Arg378has been moved over 5 Å. The loop 
following Arg
378
 (the “PPATP” loop) has significantly altered its conformation and position (e.g. the 
Cγ atom of Pro379 has moved over 10 Å). The reordering of the structure around Arg378 seems to be 
linked to other movements at Phe
47
 (1.2-Å Cα shift). These residues are contained within the one 
monomer. The phosphate of PLP binds to the side chain of Thr
294
 from one subunit and to the main 
chain of Ala
294
 from the other subunit. The hydroxyl of L-Ser makes a polar contact to the main chain 
of Ala
294
. In the other monomer, the side chain Met
104
 adjusts its conformation, and there is a slight 
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rigid body shift of Leu
105
 to Asn
106
. The side chain of Asn
100
 from the other subunit has altered its 
position, but the hydrogen bond to Lys
265
 is maintained. 
 
 
 
 
 
Figure 5. Structure of the SPT·L-serine external aldimine complex: A, overall structure of the 
SPT dimer showing one monomer in light blue and the other in purple. The residues Lys
265
 and Asn
100
 
from the light blue monomer are shown in stick form and are colored yellow. The equivalent residues 
from thepurple monomer are colored green. This clearly shows that the Asn
100
 from one monomer 
interacts with the active site of the other monomer. The PLP·L-ser external aldmine is also shown in 
stick form. B, a stereo image of an Fo −Fc electron density map contoured at 3 σ around the PLP·L-ser 
external aldimine found in the native SPT. The phases were calculated from a model that had never 
included the PLP or aldimine. 
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Figure 6. Structure of the SPT·L-serine external aldimine complex and impact of the N100Y 
HSAN1 mutation. A, a stereo image showing residues involved in binding the PLP·L-ser external 
aldimine complex are shown. His
159
, Asp
231
, His
234
, Thr
262
, Lys
265
, and Arg
378
 are from monomer A 
(light blue) in yellow stick format. Residues Thr
294
 and Asn
100
are from monomer B (purple), are 
colored green, and are annotated with anasterisk. Residues His
159
 and Arg
378
 interact with the 
carboxylate group of the L-serine; Lys
265
 (denoted by dashed lines) interacts with the hydroxyl group 
of the L-serine; and His
234
 interacts with the hydroxyl group of the PLP. Residue Asp
231
 binds to the 
nitrogen atom of the PLP cofactor, and the side chain of Asn
100
 (from monomer B) interacts with the 
backbone of Lys
265
of the opposite monomer A. B, a stereo image of an overlay of the external 
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aldimine forms of the wild-type and N100Y. The wild-type structure has been rendered with 
monomer A colored with a blue backbone and yellow side chains, and monomer B is shown with a 
purple backbone and green side chains. In the N100Y mutant, the monomer A backbone and side 
chains arecolored gold, and monomer B is colored with a red backbone and salmon pink side chains. 
The N100 side chain from monomer B of the wild-type SPT (green stick, asterisk) interacts with 
residues from monomer A. However, in the SPT N100Y mutant, the Tyr
100
 side chain has flipped into 
a pocket formed by displacement of Phe
109
 of the same monomer B, residue Asn
106
from monomer B 
has also undergone a large shift, and residue Asn
375
 from monomer A has also changed. The backbone 
containing residue Tyr
100
 has also undergone a large conformational change. C, a stereo image of an 
overlay of the external aldimine forms of the wild-type and N100Y showing the impact of mutation 
on Arg
378
 and the PPATP loop. The coloring is the same as in B. In wild-type SPT, residue Arg
378
 
(side chain yellow on the bluebackbone) is in the swung in position and interacts with the L-Ser 
carboxylic acid. In the SPT N100Y mutant, the “PPATP loop” and the Arg378 residue (backbone and 
side chain colored gold) are in the “swung out” conformation observed in the wild-type internal 
aldimine form. The interaction between Arg
378
 and Gln
357
 (both in gold) and the different positions of 
the Asn
100
and Tyr
100
 residues are shown. 
 
Structural Biology of the Holo-forms of the HSAN1 Mutant Mimics 
The wild-type SPT and N100C structures superimpose with an r.m.s. deviation of 0.2 Å along the 396 
Cα residues and are largely identical. Similarly, the N100W and N100Y mutant structures 
superimpose with 0.1 Å r.m.s. deviation for their Cα positions, mirroring their similar spectroscopic 
properties. However, both N100W and N100Y superimpose with the native structure (and N100C) 
with an r.m.s. deviation of 0.6 Å. For ease of discussion, only the differences between N100Y and the 
native enzyme are reported. The N100W structure is essentially identical to N100Y, whereas N100C 
is essentially identical to native. Reflecting the large deviation in Cα positions, there are a number of 
small shifts in secondary structure elements throughout the structure when comparing the N100Y 
mutant with the native SPT. These shifts are largely conserved, regardless of which structures one 
compares (N100W versus native, N100W versus N100C, N100Yversus N100C, and N100Y versus 
native), suggesting that they are real and not simply a crystallographic artifact. The most obviously 
visible change is the N-terminal helix (Asp
23–Gly42), which has undergone an approximately 1.7-Å 
shift. This helix is an important part of the dimeric interface of SPT 
[41]
. At the site of mutation itself, 
the tyrosine side chain has “flipped” out the pocket occupied by Asn100 (Fig. 6B). At the Cα level, this 
is a displacement of 3.4 Å and is accomplished by an almost 180° rotation of the Ramachandran angle 
at Thr
99
. As a result, the hydrogen bonds between the side chain of Asn
100
 with the key Lys
265
 from the 
other monomer have been broken. Instead, the Tyr
100
 now occupies a new pocket at the dimer 
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interface formed by hydrophobic residues from both monomers (Phe
109
 from the same monomer; 
Met
51
, Thr
72
, and Ile
69
from the other monomer) (Fig. 6B). These hydrophobic residues have adjusted 
their position to accommodate the bulky tyrosine side chain. The most pronounced of these changes 
appear to accompany the movement of Phe
109, which connects to an α-helix. Residues of the first turn 
of the helix, His
110
, Asp
111
, His
112
, Met
113
, and Glu
114
, all show disturbed side chain and main chain 
positions relative to the native structure. The main chain at Leu
105
, Asn
106
, and Gly
107
 sits opposite and 
close to Asn
100
 in the native structure. The movement of the Cα atom at position 100 by 3.4 Å causes 
Leu
105–Gly107 to undergo large positional movements (over 4 Å for the Cα positions of Gly107) and 
changes in their Ramachandran angles. 
 
Structural Biology of Wild Type and N100Y L-Ser External Aldimines 
The r.m.s. deviation between the two external aldimines, native SPT, and N100Y mutant at 0.4 Å is 
less than the value for the internal aldimine structures (0.6 Å). Thus, it appears that formation of the 
external aldimine drives N100Y toward a more “native” conformation. This can be seen most clearly 
in the loop between Tyr
100
 and Gly
107
, which is more similar to the native structure in the external 
aldimine complex. The most striking difference between the two external aldimine structures is that in 
the N100Y structure, the “PPATP loop” remains in its internal aldimine conformation, and 
consequently Arg
378
 does not enter the active site and does not make salt links with the carboxylate of 
L-ser (Fig. 6C). Rather, in the external aldimine of N100Y, Arg
378
 is hydrogen-bonded to Gln
357
, an 
interaction that is absent in the N100Y internal aldimine due to a small shift in structure. 
 
Discussion 
Mechanistic Implications 
The seminal hypothesis, forwarded by Dunathan 
[51]
 over 40 years ago, to explain how PLP-dependent 
enzymes can catalyze numerous chemical reactions is still valid. The key steps involve the 
deprotonation of the amino acid·PLP external aldmine to form the quinonoid species, which 
condenses with the incoming acyl-CoA thioester (Fig. 1). This is thought to generate a β-keto acid 
intermediate that then decarboxylates to give a product aldimine 
[23]
. The first intermediate in the 
catalytic cycle of SPT is the external aldimine formed between L-ser and PLP. Deprotonation of the 
Cα of this external aldimine intermediate is the crucial next step. In studies with ALAS, this 
deprotonation has been observed to be accelerated by over 250,000-fold by the binding of the 
incoming thioester substrate 
[14, 52]
. Studies on AONS, which uses L-alanine and pimeloyl-CoA, 
suggest that this enzyme undergoes conformational change during intermediate formation. Incubation 
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of the enzyme with palmitoyl-CoA preequilibrated with L-alanine gave a 30-ms lag before quinonoid 
formation at 486 nm was observed with a rate of 45 s
−1
 
[14]
. Recently, a thioether CoA substrate 
analogue (S-(2-oxoheptadecyl)-CoA) was shown to increase the rate of proton abstraction from the 
serine external aldimine of SPT by around 100-fold 
[50]
. 
Our new structure provides insight into the residues that control the L-Ser external aldimine 
conformation (Fig. 7, A–C). How was this intermediate trapped in the crystal? The high resolution 
data confirm that the L-serine·PLP external aldimine is sp
3
-hybridized at the Cα (the angles are 111.5, 
106.4, and 109.6°, which are close to the theoretical values for a tetrahedral carbon). In the external 
aldimine structure, the Nz atom of Lys
265
 contacts (3.4 Å) the Cα proton of the L-Ser. This double role 
for the Schiff base forming lysine was suggested by studies of members of the α-oxoamine synthase 
family 
[14, 17, 18, 20]
, and SPT has now been shown to use the same feature. The angles between each 
functional group and the N-imine (which is co-planar with the PLP ring) were measured as follows: 
H-Cα-N, 107.7°; CO2-Cα-N, 108.4°; CH2-Cα-N, 113.3°. None of these have the desired perpendicular 
orientation to the plane, indicating that in the crystal structure, the external aldimine is not in the 
optimal “Dunathan conformation” suitable for deprotonation. 
 
 
Figure 7. Schematic representation of the residues involved in SPT catalysis, conformations of 
the external aldimines, and roles of active site arginine residues in controlling: A, key residues 
involved in forming the active site are highlighted. The Arg
378
 side chain is in the swung out 
Page 20 of 28 
conformation and interacts with Gln
357
. B, binding of L-Ser leads to PLP·L-Ser external aldimine 
formation. The residues observed in the wild-type crystal structure are shown. The carboxylate of L-
Ser interacts with the side chains of His
159
 and Arg
378
, which is now in the swung in conformation. 
Rotation around the Cα–Nα bond (arrow) brings the intermediate into the desired Dunathan 
conformation shown in C. The carboxylate is shown to possibly interact with Arg
390, and the Cα-H is 
now perpendicular to the PLP ring. This is then deprotonated by Lys
265
 to form the quinonoid. D, 
stereo image of a model of the external aldimine Dunathan conformation using the external aldimine 
structure. 
If, as seems likely, palmitoyl-CoA binding leads to rapid deprotonation, we suggest that it does so by 
triggering the rotation of the external aldimine about the imine N–Cα bond. A small turn of ∼15–20° 
would bring the Cα hydrogen into the required perpendicular geometry (Fig. 7B). Of course, this 
would cause the simultaneous movement of the -CO2
−
 group and the -CH2OH side chain. Ikushiro 
proposed a role for the conserved residue Arg
390
 in the SPT mechanism 
[50]
. The structural data show 
that Arg
390
 is over 6.5 Å distant from the carboxylate; rotating around the Cα–N bond to reach the 
likely quinonoid conformation shortens this distance to 4.6 Å (Fig. 7, C and D). An additional 
rearrangement, promoted by palmitoyl-CoA binding, could allow Arg
390
 to interact with the 
carboxylate, as seen in the KBL external aldimine. We note that Arg
390
 plays an important role in 
stabilizing the conformation of Tyr
73
, which forms the active site. The rotation to form the quinonoid 
would disrupt the salt link to Arg
378
 in the absence of any additional structural adjustment. The 
interplay of Arg
390
 and Arg
378
 in interacting with the carboxylate group may be an important 
component in controlling the formation and deprotonation of the external aldimine. Together, they 
could act to pick up, ferry, then anchor the carboxylic acid group. This functional group is ultimately 
lost from the β-keto acid as CO2, and future work will be required to understand how this important 
step is controlled. Ikushiro et al. 
[50]
 also proposed a role for His
159
 acting as a hydrogen donor to 
accommodate the developing negative charge on the CO of the thioester. The structure shows that the 
Nϵ atom of His159 hydrogen-bonds to the L-serine CO2
−
 group as well as maintaining a π-stacking 
interaction with the PLP ring. This is consistent with the reported SPT H159F mutant, which bound 
L-serine weakly (Kd = 11.1 mM) and was incapable of KDS formation. Whether the residue also plays 
a role in the chemistry of the thioester activation remains an open question. 
That Arg
378
 binds to the external aldimine was unsuspected, since it required a very large 
conformational change from the holoenzyme structure. Mutation of this residue (R378A and R378N) 
reduces enzyme efficiency by over a factor of 10 (Table 1). Thus, we suggest that this residue plays 
an important, but not essential, role possibly influencing the stabilization of an intermediate after both 
substrates have bound. Weight is given to this hypothesis by the fact that R378A cannot form a 
quinonoid in the presence of the thioether analogue (Fig. 4C). The nonessential nature of the residue 
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is consistent with its lack of sequence conservation in all SPT isoforms, and an equivalent residue in 
the human SPT1/SPT2 heterodimer awaits identification. That there may be such a residue comes 
from analysis of enzymes in the α-oxoamine synthase family. In the two glycine-specific members, 
KBL and ALAS, residues Asn
50
 and Asn
54
, respectively, make direct contact with the -CO2
−
 group 
[17, 
18]
 of the amino acid. In AONS, Webster et al. 
[14]
 used the AONS-AON product external aldimine 
structure to predict that the L-alanine carboxylate would coordinate with residue Asn
47
. Sequence 
homology lines up residue Asn
74
 from S. paucimobilis SPT with the three Asn residues from AONS, 
ALAS, and KBL; however, analysis of the structure reveals that this residue in not involved in the 
active site. Thus, there is reason to suspect that some residue is required to coordinate to the 
carboxylic group of the external aldimine; however, given that the function is not essential, the 
conservation of the residue is not absolute. 
The organization of the active sites of AONS, KBL, and ALAS is different compared with the 
bacterial SPT; the constellation of residues around the PLP cofactor is conserved, but there are subtle 
differences. SPT favors L-Ser as the substrate, and in the SPT external aldimine structure, the side 
chain hydroxyl makes a number of hydrogen bonds, which could explain this preference. 
Interestingly, although SPT can form an external aldimine with L-Thr (Kd = 3.8 mM) 
[40]
, it cannot be 
deprotonated to the quinonoid in our hands (data not shown). Looking at the structure of the aldimine, 
the additional methyl group of L-Thr would appear to clash with Ser
102
 and Arg
378
 in the proposed 
quinonoid model. In the ALAS structure, Thr
83
 would seem to select against any substituent at the Cα 
position, explaining the preference for Gly of this enzyme. 
 
Mimics of the HSAN1 Disease Causing Mutations 
The two most common mutations (C133W and C133Y) associated with the human disease HSAN1 
have intrigued a number of researchers as to how they impact on sphingolipid metabolism and 
regulation. The fact that these mutations are in the inactive subunit, LCB1 (SPT1), has added to their 
scientific interest. Tissue from HSAN1 patients contains relatively normal levels of total sphingolipids 
[10, 31,32]
 However, there are differing reports as to the intrinsic SPT activity of cells from HSAN1 
individuals, and questions remain as to the precise consequence of the HSAN1 mutants on SPT 
turnover, stability, and regulation. Gable et al. 
[30]
 produced mutants of the yeast lcb1 gene (C180Y 
and C180W) that mimic the HSAN1 substitutions (C133W and C133Y). Interestingly, these 
mutations dominantly inactivated the SPT activity of the yeast LCB1·LCB2 heterodimeric complex. 
This study proposed that the LCB1 HSAN1 mutations perturbed the active site of the LCB1·LCB2 
dimer. McCampbell et al. 
[31]
 expressed the human LCB1 C133W mutant in a transgenic mouse and 
found that the SPT activity was decreased in various tissues and mice developed a number HSAN1 
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symptoms. However, the levels of total ceramide in these mice were unchanged, as was also observed 
in human HSAN1 individuals. This indicates that to some extent, SPT activity is preserved, and the 
mutants have a more subtle effect than simple loss of activity. It would also indicate that there is some 
regulation of sphingolipid biosynthesis after KDS formation by SPT. 
We had previously mapped the human Cys
133
 residue to Asn
100
 on the bacterial SPT 
[41]
. We first 
engineered an N100C mutation as a better mimic for the human enzyme. This mutant enzyme behaves 
within the sensitivity of our UV-visible spectroscopic, kinetic, and high resolution structural analyses 
as native. This gave us confidence that the other mutations at Asn
100
 in the bacterial enzyme should 
provide a meaningful insight into human SPT. 
N100W and N100Y mutants displayed marked spectroscopic, enzymatic, and structural differences 
when compared with wild-type SPT. Although both mutants are severely compromised in their 
activity, importantly, they do retain the ability to make the desired KDS product. It was obvious from 
the distinctive UV-visible properties of PLP-containing holo-forms of the enzymes that the mutants 
had altered the cofactor's chemical environment (Fig. 2, A–D). This change in the chemical 
environment apparently disturbs catalysis. After formation of an external aldimine, deprotonation 
gives a quinonoid intermediate (Fig. 1), which has been detected for both AONS and ALAS enzymes 
[14, 52]
. In the native SPT enzyme, the quinonoid form can be detected by adding the palmitoyl-CoA 
thioether analog. However, in the N100Y mutant, the signal for the quinonoid is essentially absent, 
indicating that the stabilization of this intermediate is significantly decreased (Fig. 4, A and B). In the 
wild-type holo-SPT (and N100C), the side chain of one monomer makes a direct contact with the 
amide backbone of the conserved PLP Schiff base Lys
265
 of the other monomer. This hydrogen bond 
is lost by the disruption introduced by the mutation. We suggest that this would increase the mobility 
of the internal aldimine. The most striking observation is that the N100Y and N100W mutations 
cause, because of the key location of Asn
100
 at the dimer interface, complex structural changes to 
ripple across the dimer interface (Fig. 6B). A striking illustration of this can be seen in the external 
aldimine of N100Y, particularly the role of Arg
378
. In the native enzyme, this residue plays an 
important role in binding to the carboxylate of the external aldimine, but in the N100Y mutant, Arg
378
 
remains uninvolved with the intermediate (Fig. 6C). Although it is difficult to identify a clear cut 
interaction that disfavors Arg
378
 from entering the active site, this residue is in contact with Leu
105
 
from the other subunit. Leu
105
 is one of the residues directly affected by the mutation at Asn
100
. The 
change in Leu
105
 position introduced by the mutation would increase the van der Waals contact 
between Arg
378
 (in the “swung in” state) and Leu105 in the mutant. It is this ability for structural 
changes to “reach across the interface” that we propose underlies the C133W and C133Y mutation 
effects in HSAN1. The perturbations in the neighboring structure give rise to the changed chemical 
environment of both the internal and external aldimine, altering the enzyme function. 
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Combined with previous studies on AONS, ALAS, and KBL, the SPT data presented here shed more 
light on the catalytic mechanism employed by members of the α-oxoamine synthase family. The 
eukaryotic SPT heterodimeric isozymes appear to be more complex than their bacterial homologs, 
since a third, tissue-specific SPT subunit has been identified recently 
[34]
. Furthermore, an abnormal, 
“dead end” sphingolipid product, 1-deoxysphinganine (also known as the natural product 
“spisulosine”), formed by SPT using L-Ala as a substrate, has been identified in mammalian cells [53, 
54]
. Whether the SPT HSAN1 mutations impact directly on substrate and product specificity requires 
further detailed investigation. In the absence of large amounts of homogenous eukaryotic complexes, 
the bacterial enzymes provide some insight into how the wild-type and mutant forms behave and aid 
in the design of isolation strategies for the more complex SPTs 
[55]
. Studies aimed at the capture of 
complexes of various SPTs with a range of substrates, products, and inhibitors are under way.  
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